Zura Bio Ltd (ZURA) Noticias

Form 8-K - Current report

Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in Q4 2024 and hidradenitis suppurativa...

Form 8-K - Current report

Zura Bio to Participate in Two Upcoming Investor Conferences in November

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for...

Form 8-K - Current report

Form 8-K - Current report

Form S-3/A - Registration statement under Securities Act of 1933: [Amend]

Form EFFECT - Notice of Effectiveness

Form EFFECT - Notice of Effectiveness

Form 8-K - Current report

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Zura Bio to Present at Three Upcoming Investor Conferences in September

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for...

Form 8-K - Current report

Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Presented data for tibulizumab at EULAR 2024, highlighting the potential relevance of dual-inhibition of both IL-17A and BAFF in autoimmune and...

Form 425 - Prospectuses and communications, business combinations